Switch theme
Sign up to access all valuation multiples
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
2010
3.5K+
LTM Revenue $875M
LTM EBITDA $180M
$3.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Henlius Biotech has a last 12-month revenue (LTM) of $875M and a last 12-month EBITDA of $180M.
In the most recent fiscal year, Henlius Biotech achieved revenue of $731M and an EBITDA of $171M.
Henlius Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Henlius Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $875M | XXX | $731M | XXX | XXX | XXX |
| Gross Profit | $640M | XXX | $534M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $180M | XXX | $171M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $63.0M | XXX | $120M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $125M | XXX | $105M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $341M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Henlius Biotech's stock price is HKD 47 (or $6).
Henlius Biotech has current market cap of HKD 25.4B (or $3.2B), and EV of HKD 28.5B (or $3.6B).
See Henlius Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6B | $3.2B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Henlius Biotech has market cap of $3.2B and EV of $3.6B.
Henlius Biotech's trades at 5.0x EV/Revenue multiple, and 21.2x EV/EBITDA.
Equity research analysts estimate Henlius Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Henlius Biotech has a P/E ratio of 28.1x.
See valuation multiples for Henlius Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 21.9x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBIT | 62.7x | XXX | 30.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.1x | XXX | 30.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 70.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHenlius Biotech's last 12 month revenue growth is 7%
Henlius Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Henlius Biotech's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Henlius Biotech's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Henlius Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Henlius Biotech acquired XXX companies to date.
Last acquisition by Henlius Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Henlius Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Henlius Biotech founded? | Henlius Biotech was founded in 2010. |
| Where is Henlius Biotech headquartered? | Henlius Biotech is headquartered in Hong Kong. |
| How many employees does Henlius Biotech have? | As of today, Henlius Biotech has 3.5K+ employees. |
| Is Henlius Biotech publicy listed? | Yes, Henlius Biotech is a public company listed on HKG. |
| What is the stock symbol of Henlius Biotech? | Henlius Biotech trades under 02696 ticker. |
| When did Henlius Biotech go public? | Henlius Biotech went public in 2019. |
| Who are competitors of Henlius Biotech? | Similar companies to Henlius Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Henlius Biotech? | Henlius Biotech's current market cap is $3.2B |
| What is the current revenue of Henlius Biotech? | Henlius Biotech's last 12 months revenue is $875M. |
| What is the current revenue growth of Henlius Biotech? | Henlius Biotech revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Henlius Biotech? | Current revenue multiple of Henlius Biotech is 4.5x. |
| Is Henlius Biotech profitable? | Yes, Henlius Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Henlius Biotech? | Henlius Biotech's last 12 months EBITDA is $180M. |
| What is Henlius Biotech's EBITDA margin? | Henlius Biotech's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Henlius Biotech? | Current EBITDA multiple of Henlius Biotech is 21.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
